11/4/2026

speaker
Conference Operator
Operator

Hello and welcome to Acadia Pharmaceuticals' third quarter earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, please press star 1 on your telephone keypad. I would now like to turn the conference over to Al Kildani, Senior Vice President, Investor Relations and Corporate Communications. You may begin.

speaker
Al Kildani
Senior Vice President, Investor Relations and Corporate Communications

Good afternoon and thank you for joining us on today's call to discuss Acadia's third quarter 2026 financial results. Joining me on the call today from Acadia are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks, followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brand's debut in New Plaza. Also joining us today is Dr. Sanjeev Pathak, SVP and Head of Clinical Development, who will provide an update on our pipeline programs, and Mark Schneyer, our Chief Financial Officer who will review the financial highlights. Catherine will then provide some closing remarks before we open up the call for your questions. We are using supplemental slides which are available on our website in the events and presentations section. On today's call, both GAAP and non-GAAP financial measures will be discussed including non-GAAP New Plaza net sales and non-GAAP total revenues. The non-GAAP financial measures that are also referred to as adjusted financial measures All references to non-GAAP are reconciled with the most directly comparable GAAP financial measures in our earnings press release and slide presentation, which has been posted on the investors page of the company's website. Before proceeding, I would like to remind you that during our call today, we will be making several forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including goals, expectations, plans, prospects, growth potential, timing of events, future results, and financial guidance, are based on current information, assumptions, and expectations that are inherently subject to change and involve several risks and uncertainties that may cause results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. We were cautioned not to place undue reliance on these forward-looking statements, which are made only as of today's date, and we assume no obligation to update or revise these forward-looking statements as circumstances change, except as required by law. I'll now turn the call over to Catherine for opening remarks.

speaker
Catherine Owen Adams
Chief Executive Officer

Thank you, Al, and good afternoon, everyone. Quarter 3 was another strong quarter for Acadia, one that demonstrates the strength of our commercial foundation and the progress we are making to translate that strength into our next chapter of growth. In the third quarter, we delivered total revenues of $342 million, representing 22% year-over-year growth on an adjusted basis. Debut delivered record net sales of $140 million, up 39% year-over-year. Debut sticks is expanding our opportunity in several different ways. Current patients who want to switch to sticks New patients who are trying debut for the first time and patients who previously stopped treatment and are coming back to try again with STIX. Given this momentum, we are raising our 2026 debut guidance and we remain confident that we can reach $700 million in debut sales by the end of 2028. We also achieved an important IP milestone during the quarter, receiving a USPTO Notice of Allowance for an important new patent covering the weight-banded dosing regimen used in both Debut Oral Solution and Debut Stix. Following issuance with pediatric exclusivity, the patent is expected to provide U.S. protection for both formulations of Debut through March 2041, extending patent protections by nearly five years. Following the successful completion of our Phase III trial for Debut in Japan, We are focused on identifying the right distribution partner while preparing for an expected 2027 regulatory submission to support market entry and remain committed to bringing debut to patients there. New Plaza delivered $202 million in net sales, up 12% year-over-year on an adjusted basis, with virtually all of that growth driven by patient demand through volume. As we approach the end of the year, we are narrowing our New Plazard guidance and remain confident that we are on track toward our ambition to reach approximately $1 billion in New Plazard net sales by the end of 2028. Tom will provide additional color on the commercial drivers behind our performance on both brands. Turning to our pipeline, the Phase 2 portion of our radiant program of remnophamperin in Alzheimer's disease psychosis Thank you for joining us today. through the six-week treatment period on both the primary and key secondary endpoints, along with a favorable safety and tolerability profile similar to placebo. Based on these findings, we are focusing our phase three program on the 60 milligram dose and taking additional steps designed to optimize for potential positive phase three outcomes. The more we have learned from these data, the more confident we have become in the path forward for the program. The findings from our Radiant Phase 2 in ADP also reinforce our confidence in the opportunity in Lewy Body Dementia Psychosis. We remain excited about the potential for Rheumatoid Cancer in this population and are pleased to announce that we expect Phase 2 results from the Illumerex study in the fourth quarter of 2027. Taken together, remlifanserin represents an important potential growth franchise across both ADP and LVDP, both areas of huge unmet medical need with an approximately $4 billion combined peak sales opportunity. Our priority now is to generate the clinical evidence needed to validate that opportunity. Beyond remlifanserin, we are advancing our broader pipeline of promising programs that we believe have the potential to address significant unmet needs and create long-term value. An additional data readout for our Norlite Phase 2 study of ACP211, our once-a-day oral deuterated form of arnolketamine for the treatment of major depressive disorder, is now expected in the second half of 2027. We believe ACP211 has the potential to address significant unmet need in major depressive disorder specifically around the patient and clinician experience. And we look forward to sharing more on this program as we move into 2027. When you step back and look at the full picture, from the answer in an ADP and LBDP, ACP 211 in MDD, and some of our earlier stage programs, we see multiple independent paths to add potential value across large, higher met need markets, representing combined peak sales potential of approximately The opportunity is significant, but our conviction and investment will continue to be guided by the evidence each program generates. Before I hand over a brief update on our R&D leadership, today's pipeline update will be delivered by Dr. Sanjeev Patak, our Senior Vice President and Head of Clinical Development. Many of you will know Sanjee from our R&D day or from prior investor conferences, and I think you'll find his perspective as a double board certified psychiatrist on the remlifanserin data particularly valuable. As we indicated in April, Dr. Liz Thompson has now retired from her role as head of R&D. Liz has made an extraordinary contribution during her tenure at Acadia, and we are deeply grateful for her leadership. She remains engaged with us as a valued consultant, and we wish her very well in her retirement. We do expect to announce our new head of R&D in the near term. In the meantime, R&D leadership responsibilities are being shared by Sanjeev along with other members of our R&D leadership team. With that, I'll hand the call over to Tom to walk through our commercial performance in detail.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation